(Total Views: 813)
Posted On: 08/20/2021 8:47:31 PM
Post# of 149235
NP vs BP.
Nader has not had a competent law firm like BBOTS tell the court that he did SEC violations nor have they had them say he had a “false statement” (in court that) would be punishable by “fine or imprisonment.” Like BP has with (Ex. G).
Please note that a PHANTOM lawsuit to help shorties accuse of SEC violations against CYDY management. They mainly mention their trades. In contrast, we’ve seen how much “13D or the group” trade. -most sales are after PRs.
Furthermore, if the 13D were miraculously allowed to continue a proxy, I question if BP would even be able to practice his MD since it might now be in question by the board.
NP raised enough money to avoid bankruptcy and hasn’t struggled with less data than they have now. He said he didn’t get his salary for a year in a RECENT video to show that he’s not lying. Moreover, he sold shares (a method of his pay) to pay Samsung, and that’s why in Q3-Q4 we will have plenty more batches of LL to distribute. (See 10k).
Based on demand, likely a negotiated BIOMM new manufacturing partnership might be in play. Reminder: BIOMM partnership is for all LL indications.
A group can go on Reddit and make conspiracy theories that NP submitted a faulty BLA for a bonus set of shares, when in reality the BLA could have been submitted to show PROOF that BP didn’t do his work correctly. Which is why NP said, NO ONE has turned it in correctly.
The closest is Recknor, with minor corrections. In fact, I suspect it’s already been done, since NP said the FDA noted the small corrections WITHIN 30 days. (We submitted it 6/30- 7/1) and we are expected to TURN MORE / OR the rest by September 1st.
CR vs BP
No 13D supporter seem to have taken into account how Recknor has improved CytoDyn.
"Dr. Recknor served as a principal investigator in over 100 clinical trials for numerous global pharmaceutical companies including Amgen, AstraZeneca, Eli Lilly, Glaxo SmithKline, Merck, Novartis and Pfizer. He has a deep background in clinical research with over 40 published research studies and co-authored several research abstracts."
Recknor turned over ownership of his clinic to not have a conflict of interest to work DIRECTLY with CYDY. BPs conflict of interest is highlighted several times.
Recknor is working in synergetic fashion with CYDY, as opposed to BP trying to have CYDY buy out his company.
Lastly, Recknor bought $1M in open market BEFORE working with the CYDY, because he was familiar with the MOA before he used LL on himself for C19. In contrast, BP has bought ZERO shares, while earning $90K from CytoDyn.
BP beneficially owned shares by BP are directly owned by IncellDx to which he’s CEO.
Note on seperate occasions, BP and IncellDx reached agreements with CytoDyn(see related party transactions).
Finally:
BP has been accused of taking patents before:
“Prior to Environs existence and without any involvement from Mr. Drew's, Dr. Patterson OBTAINED PATENTS for his technology....Dr. Drew's NEVER ASSIGNED or sold his patents...”
“Defendants likewise failed to disclose Patterson’s attempt to obtain a patent on CytoDyn’s intellectual property”
In summary:
We were lied to when they said IncellDx filed a patent, it was BP after his TedTalk of LL. In fact, two applications were denied.
Our law firm is or is in the process of deposition with the group.
They’re asking for the plan to finally be released and to see if the $350M B/O overlaps their plan.
It looks like they have many SEC violations via soliciting, etc
New investors:
22 cancer Indications: Strong volunteered “Anectodal” stories for multiple cancers.
mTNBC - 30 patients. Decreases in CAMLs after 4 Doses of Leronlimab were Identified in Over 70% of Patients. With a 450% Significant Increase in Overall Survival at 12-Month Analysis.
HIV: P-Value: 0.0032, BLA = some corrections to continue filing the easy part, mainly by Dr. Nithya Ray
COVID-19:
CD10 (moderate) had 64% less severe adverse effects.
CD12 (severe/critical) had 21% less adverse effects, 82% efficacy in 2 weeks.
Long Haulers - Exploratory trial hit 8 statistically significant PValue in LL arm of 25 patients. Improving 18/24, with possible improvement in even more. Biomarkers to prove the change, etc were noted and will be in the top line data.
Nash - interim results due soon. In fact I suspect Scott Kelly might present some more data at the World Antiviral Congress - Nov 30–Dec 2, 2021.
Possible BTD: mTNBC, NASH, Covid indications.
Management recently enabled half their pay to become shares.
Nader has not had a competent law firm like BBOTS tell the court that he did SEC violations nor have they had them say he had a “false statement” (in court that) would be punishable by “fine or imprisonment.” Like BP has with (Ex. G).
Please note that a PHANTOM lawsuit to help shorties accuse of SEC violations against CYDY management. They mainly mention their trades. In contrast, we’ve seen how much “13D or the group” trade. -most sales are after PRs.
Furthermore, if the 13D were miraculously allowed to continue a proxy, I question if BP would even be able to practice his MD since it might now be in question by the board.
NP raised enough money to avoid bankruptcy and hasn’t struggled with less data than they have now. He said he didn’t get his salary for a year in a RECENT video to show that he’s not lying. Moreover, he sold shares (a method of his pay) to pay Samsung, and that’s why in Q3-Q4 we will have plenty more batches of LL to distribute. (See 10k).
Based on demand, likely a negotiated BIOMM new manufacturing partnership might be in play. Reminder: BIOMM partnership is for all LL indications.
A group can go on Reddit and make conspiracy theories that NP submitted a faulty BLA for a bonus set of shares, when in reality the BLA could have been submitted to show PROOF that BP didn’t do his work correctly. Which is why NP said, NO ONE has turned it in correctly.
The closest is Recknor, with minor corrections. In fact, I suspect it’s already been done, since NP said the FDA noted the small corrections WITHIN 30 days. (We submitted it 6/30- 7/1) and we are expected to TURN MORE / OR the rest by September 1st.
CR vs BP
No 13D supporter seem to have taken into account how Recknor has improved CytoDyn.
"Dr. Recknor served as a principal investigator in over 100 clinical trials for numerous global pharmaceutical companies including Amgen, AstraZeneca, Eli Lilly, Glaxo SmithKline, Merck, Novartis and Pfizer. He has a deep background in clinical research with over 40 published research studies and co-authored several research abstracts."
Recknor turned over ownership of his clinic to not have a conflict of interest to work DIRECTLY with CYDY. BPs conflict of interest is highlighted several times.
Recknor is working in synergetic fashion with CYDY, as opposed to BP trying to have CYDY buy out his company.
Lastly, Recknor bought $1M in open market BEFORE working with the CYDY, because he was familiar with the MOA before he used LL on himself for C19. In contrast, BP has bought ZERO shares, while earning $90K from CytoDyn.
BP beneficially owned shares by BP are directly owned by IncellDx to which he’s CEO.
Note on seperate occasions, BP and IncellDx reached agreements with CytoDyn(see related party transactions).
Finally:
BP has been accused of taking patents before:
“Prior to Environs existence and without any involvement from Mr. Drew's, Dr. Patterson OBTAINED PATENTS for his technology....Dr. Drew's NEVER ASSIGNED or sold his patents...”
“Defendants likewise failed to disclose Patterson’s attempt to obtain a patent on CytoDyn’s intellectual property”
In summary:
We were lied to when they said IncellDx filed a patent, it was BP after his TedTalk of LL. In fact, two applications were denied.
Our law firm is or is in the process of deposition with the group.
They’re asking for the plan to finally be released and to see if the $350M B/O overlaps their plan.
It looks like they have many SEC violations via soliciting, etc
New investors:
22 cancer Indications: Strong volunteered “Anectodal” stories for multiple cancers.
mTNBC - 30 patients. Decreases in CAMLs after 4 Doses of Leronlimab were Identified in Over 70% of Patients. With a 450% Significant Increase in Overall Survival at 12-Month Analysis.
HIV: P-Value: 0.0032, BLA = some corrections to continue filing the easy part, mainly by Dr. Nithya Ray
COVID-19:
CD10 (moderate) had 64% less severe adverse effects.
CD12 (severe/critical) had 21% less adverse effects, 82% efficacy in 2 weeks.
Long Haulers - Exploratory trial hit 8 statistically significant PValue in LL arm of 25 patients. Improving 18/24, with possible improvement in even more. Biomarkers to prove the change, etc were noted and will be in the top line data.
Nash - interim results due soon. In fact I suspect Scott Kelly might present some more data at the World Antiviral Congress - Nov 30–Dec 2, 2021.
Possible BTD: mTNBC, NASH, Covid indications.
Management recently enabled half their pay to become shares.
(24)
(0)Scroll down for more posts ▼
